The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

The condition appears to be triggered when the optic nerve swells, choking off its blood supply because the nerve's pathway ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

“While they act through different biochemical pathways, both GLP-1 agonists and SGLT2 inhibitors have been shown to decrease the risk of cardiovascular disease. They both likely accomplish this by ...

Results of a placebo-controlled trial support prior observational findings that GLP-1 agonists can help reduce alcohol ...

New research explores the wide world of the positives, and potential drawbacks, of new obesity medications. And each brings a new consideration for physicians.

Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout ...

Share on Pinterest Women with diabetes may get the strongest cardiovascular protection from GLP-1 agonists. Image credit: Kathryn Gamble for The Washington Post via Getty Images. Diabetes, a ...